JP7596260B2 - 可溶性ｂｃｍａに対する抗体 - Google Patents

可溶性ｂｃｍａに対する抗体 Download PDF

Info

Publication number
JP7596260B2
JP7596260B2 JP2021516763A JP2021516763A JP7596260B2 JP 7596260 B2 JP7596260 B2 JP 7596260B2 JP 2021516763 A JP2021516763 A JP 2021516763A JP 2021516763 A JP2021516763 A JP 2021516763A JP 7596260 B2 JP7596260 B2 JP 7596260B2
Authority
JP
Japan
Prior art keywords
sbcma
antibody
seq
monoclonal antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501389A5 (https=
JP2022501389A (ja
Inventor
キエルツジェフスカ，アグニェシュカ
チャン，ブライアン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2022501389A publication Critical patent/JP2022501389A/ja
Publication of JP2022501389A5 publication Critical patent/JP2022501389A5/ja
Priority to JP2024100215A priority Critical patent/JP2024147571A/ja
Application granted granted Critical
Publication of JP7596260B2 publication Critical patent/JP7596260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021516763A 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体 Active JP7596260B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024100215A JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738997P 2018-09-28 2018-09-28
US62/738,997 2018-09-28
PCT/US2019/053433 WO2020069303A1 (en) 2018-09-28 2019-09-27 Antibodies against soluble bcma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024100215A Division JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Publications (3)

Publication Number Publication Date
JP2022501389A JP2022501389A (ja) 2022-01-06
JP2022501389A5 JP2022501389A5 (https=) 2022-10-04
JP7596260B2 true JP7596260B2 (ja) 2024-12-09

Family

ID=68296657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516763A Active JP7596260B2 (ja) 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Country Status (11)

Country Link
US (1) US11505614B2 (https=)
EP (1) EP3856781A1 (https=)
JP (2) JP7596260B2 (https=)
KR (1) KR20210068408A (https=)
CN (1) CN112703204B (https=)
AR (1) AR116548A1 (https=)
BR (1) BR112021005669A2 (https=)
MA (1) MA53732A (https=)
TW (1) TW202028239A (https=)
UY (1) UY38393A (https=)
WO (1) WO2020069303A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3819007T (lt) * 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
JP2025542567A (ja) * 2022-11-04 2025-12-26 ミンク セラピューティクス，インコーポレイティッド Ｂ細胞成熟抗原（ｂｃｍａ）キメラ抗原受容体インバリアントナチュラルキラーｔ細胞及びその用途
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN119529089B (zh) * 2023-08-28 2025-11-18 菲鹏生物股份有限公司 一种抗生长刺激表达基因2蛋白的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018050627A (ja) 2011-11-15 2018-04-05 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
JP2018087190A (ja) 2011-05-27 2018-06-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1985A (en) 1841-02-18 Charles m
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
NO2748201T3 (https=) 2011-08-23 2018-05-12
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
ES2898329T3 (es) * 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087190A (ja) 2011-05-27 2018-06-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
JP2018050627A (ja) 2011-11-15 2018-04-05 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Haematologica，2017年，Volume 102, No.4，pp.785-795

Also Published As

Publication number Publication date
TW202028239A (zh) 2020-08-01
JP2024147571A (ja) 2024-10-16
US11505614B2 (en) 2022-11-22
WO2020069303A1 (en) 2020-04-02
BR112021005669A2 (pt) 2021-06-22
KR20210068408A (ko) 2021-06-09
MA53732A (fr) 2022-01-05
JP2022501389A (ja) 2022-01-06
EP3856781A1 (en) 2021-08-04
CN112703204B (zh) 2024-10-01
CN112703204A (zh) 2021-04-23
US20200102398A1 (en) 2020-04-02
AR116548A1 (es) 2021-05-19
UY38393A (es) 2020-03-31

Similar Documents

Publication Publication Date Title
JP7623006B2 (ja) 特異的結合剤により認識されるエピトープタグ
JP2024147571A (ja) 可溶性ｂｃｍａに対する抗体
US9458244B2 (en) Single chain multivalent binding protein compositions and methods
US12221484B2 (en) Anti-NMDA receptor antibodies and methods of use
JP7750852B2 (ja) ムチン１７に対する抗体及びその使用
EP3533459A1 (en) Anti-pla2-gib antibodies and the uses thereof
WO2019156223A1 (ja) チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CN115960219B (zh) 抗SARS-CoV-2刺突蛋白S1的单克隆抗体及其应用
CN113366021A (zh) 糖基化Apo J特异性抗体及其用途
TW202216758A (zh) 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組
KR20250154412A (ko) 항원 결합 분자 및 사용 방법
WO2019084427A1 (en) T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
TW201739769A (zh) 人源化之單株抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7596260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150